Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
108 hedge funds and large institutions have $864M invested in Rubius Therapeutics, Inc in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 44 increasing their positions, 27 reducing their positions, and 14 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 27
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
3% more funds holding
Funds holding: 105 → 108 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less call options, than puts
Call options by funds: $614K | Put options by funds: $617K
44% less capital invested
Capital invested by funds: $1.55B → $864M (-$682M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.9M |
| 2 |
JP Morgan Chase
New York
|
+$9.83M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$8.76M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$3.29M |
| 5 |
Morgan Stanley
New York
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$6.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.59M |
| 3 |
PP
PDT Partners
New York
|
-$1.18M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$824K |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$730K |
RUBY Hedge Fund Activity: Q4 2021 in Review
108 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q4 2021, worth a combined $864M — down 44% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RUBY positions and 14 closed out — a net gain of 4 holders — while 44 added to existing stakes and 27 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $12.9M. The largest seller was Artal Group, cutting an estimated $6.3M.
- 108 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q4 2021, up from 105 in Q3 2021.
- Funds reported $864M of Rubius Therapeutics, Inc stock for Q4 2021, down 44% quarter-over-quarter.
- 18 funds opened new Rubius Therapeutics, Inc positions in Q4 2021 and 14 closed out, a net change of +4 holders.
- The largest Rubius Therapeutics, Inc buyer in Q4 2021 was T. Rowe Price Associates, an estimated $12.9M added.
- The largest Rubius Therapeutics, Inc seller in Q4 2021 was Artal Group, an estimated $6.3M sold.
Based on aggregated 13F filings for Q4 2021.